Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E3BH
|
||||
| Former ID |
DAP000469
|
||||
| Drug Name |
Ridogrel
|
||||
| Synonyms |
Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute myocardial infarction [ICD9: 410; ICD10:I21-I22] | Approved | [1] | ||
| Therapeutic Class |
Gastrointestinal Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H17F3N2O3
|
||||
| Canonical SMILES |
C1=CC(=CC(=C1)C(F)(F)F)C(=NOCCCCC(=O)O)C2=CN=CC=C2
|
||||
| InChI |
1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
|
||||
| InChIKey |
GLLPUTYLZIKEGF-HAVVHWLPSA-N
|
||||
| CAS Number |
CAS 110140-89-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Binder | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Inhibition of cytochromes p450: existing and new promising therapeutic targets. Drug Metab Rev. 2007;39(2-3):481-99. | ||||
| REF 2 | Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.